StockIQ.techCSPC Pharmaceutical Group Limited (1093.HK) Stock Analysis
Free AI-powered analysis and research for CSPC Pharmaceutical Group Limited stock
Sector: Healthcare
1093.HK snapshot
Data as of 3 Nov 2026 close. Updated daily.
CSPC Pharmaceutical Group Limited scores 77/100 on StockIQ's model, which reads as strongly positive signals overall. The price is below its 200-day average and at 30% of its 52-week range, up 6.8% over the past year. Latest reported figures show a profit margin of 23.7%, return on equity of 20.9% and revenue growth of +93.8%.
What is driving the score
- Strong Downtrend: -12
- MACD Bearish: -8
- Low P/E (11.0): +10
- Strong Revenue Growth (93.8%): +8
- Excellent Profit Margin (23.7%): +10
- Low Debt (0.02 D/E): +8
- Strong Liquidity (2.14 Current Ratio): +8
- Excellent ROE (20.9%): +8
- Long-term Downtrend: -8
- Up Over 1 Year (+6.8%): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 1093.HK report
CSPC Pharmaceutical Group Limited (1093.HK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 1093.HK Now →📰 Latest Update
CSPC Pharmaceutical Group (SEHK:1093) Stock May Be 44% Undervalued On RSV Trial Start
Wed, October 28, 2026 at 5:08 PM UTC 4 min read
CSPC Pharmaceutical Group (SEHK: 1093) has been identified as potentially 44% undervalued following the initiation of its respiratory syncytial virus (RSV) trial. This development is significant for investors as it suggests a promising growth opportunity, potentially enhancing the company's market position and future earnings. Analysts recommend monitoring the trial's progress, as successful outcomes could lead to a substantial increase in stock value.